SLGL | tickerfilter.com

Fundamental analysis

23%

Profitability 25%

Dept financing 18%

Liquidity 50%

Performance 15%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

3.82%

1 Month

-1.84%

3 Months

18.40%

6 Months

-6.05%

1 Year

-43.90%

2 Year

-83.09%

Key data

Stock price

$0.59

P/E Ratio

0.00

DAY RANGE

$0.58 - $0.62

EPS

-$1.44

52 WEEK RANGE

$0.33 - $1.65

52 WEEK CHANGE

-$43.90

MARKET CAP

19.470 M

YIELD

N/A

SHARES OUTSTANDING

27.858 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

2.82

PUBLIC FLOAT

AVERAGE 10 VOLUME

$23,498

AVERAGE 30 VOLUME

$43,996

Company detail

CEO: Alon Seri-Levy
Region: US
Website: sol-gel.com
Employees: 50
IPO year: 2018

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Sol-Gel Technologies Ltd. focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system. Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris, Epsolay, SGT-210, and Erlotinib, Tapinarof, and roflumilast are the company's lead product candidates.

SLGL - Sol-Gel Technologies Ltd.